Participated · Seed · Dec 2024

MoldCo operates the first clinician-led digital health service focused on making mold detox a routine component of preventative care. Through its telehealth platform, patients can obtain symptom screening, advanced biomarker lab tests starting at $99, virtual consultations with certified mold-toxicity specialists, and prescription therapies shipped directly to their homes. Typical treatment plans cost $150–$300 per month, positioning MoldCo as a far cheaper alternative to fragmented, in-person options that can run into the tens of thousands of dollars. The company is already offering lab testing in 46 states and clinical care in select states such as Florida, Massachusetts, Michigan, Ohio, and Texas, with nationwide coverage targeted for 2026. Near-term priorities include expanding its specialist network, enhancing proprietary care technology, scaling patient onboarding, and launching clinical research collaborations to raise physician and public awareness. Backed by leading physicians, researchers, and tech VCs, MoldCo has raised $11 million to date to accelerate these initiatives.

Participated · Seed · Oct 2024

Integrated Biosciences combines synthetic biology, optogenetics and AI/machine-learning to generate highly specific cellular phenotypes and discover precise small-molecule drug candidates for age-related diseases. The company has published work in journals including Nature, Nature Aging and Cell Systems and last year pioneered an AI-driven discovery of a structural class of antibiotics. It is developing a portfolio of preclinical-stage assets that target fundamental, age-related pathways at the phenotypic level. Integrated pursues a multi-asset business model, advancing programs via company-led development and co-development partnerships and maintains collaborations with private partners and Illumina Ventures Labs. The company announced it closed a $17.2 million seed financing to scale its platform, advance clinical development of its small-molecule portfolio, and accelerate commercialization efforts.

Participated · Seed · Mar 2024

Portal builds a proprietary mechanoporation-based platform to enable efficient, scalable delivery of RNA, gene editors, probes, and other molecules into hard-to-transfect cells across diverse cell types and workflows. The company targets applications across novel drug discovery workflows, multi-perturbation AI data generation, and next-generation cell therapies, and integrates with high-throughput robotics and GMP manufacturing systems. Portal reports commercial traction with more than 100 customer sites, including public collaborations or use by Microsoft, Merck, AbbVie, Mass General Brigham, the Ragon Institute, and Purdue University. Use cases highlighted include high-throughput, physiologically relevant screening, generation of model-training biological data, and same-day circRNA-based multifunctional CAR-T production at the point of care. DARPA has expanded an initial $8M contract and is supporting commercialization through its EEI program, underscoring validation for Portal's point-of-care cell therapy manufacturing efforts. The company states it has achieved meaningful commercial revenue and technical validation from large pharma and academic partners.

Participated · Seed · Nov 2021

Wave Life is developing a mobile platform that combines Acceptance and Commitment Therapy techniques with video-game-inspired, immersive exercises to help young adults clarify values and make healthier decisions. Founded by Stanford psychiatry professor and clinical psychologist Dr. Sarah Adler, the company takes an inclusivity-first approach, explicitly designing for GSRM, BIPOC and other historically overlooked populations. Its ‘digital ecosystem’ pairs evidence-based content with lower-cost human support, such as health coaches, to scale care efficiently. The product is currently in development, with a public test planned for early next year and a wider consumer launch later in the year. By integrating engagement mechanics learned from the gaming industry, Wave aims to keep users returning to the app, ultimately driving measurable mental-health outcomes. Financially, the company secured a $2 million pre-seed round to fund product development and initial market entry.

Participated · Seed · Oct 2021

Aqua Cultured Foods develops whole‑muscle seafood alternatives — calamari, shrimp, scallops, tuna and whitefish filets — plus minced fillings for dumplings, ravioli and sushi. The company uses proprietary mycoprotein (fungi) fermentation processes with no animal inputs or genetic modification and says its products are optimized to be consumed raw with textures close to conventional seafood. Aqua is Chicago‑based and recently acquired a 5,000‑square‑foot food‑grade pilot facility and expects to begin manufacturing first products (tuna, scallops and ground shrimp) by early summer. The team says a 450‑square‑foot grow space could produce between 5,000 and 10,000 pounds of product, supporting decentralized manufacturing for future market expansion. Planned uses of the new funding include hiring, expanding restaurant and foodservice introductions, and running chef pop‑ups to gauge demand. Financially, the company announced a $5.5M seed round and has raised just over $8M to date. Aqua Cultured Foods makes animal-free seafood analogs using a microbial fermentation process and a proprietary strain of fungi. The company produces a “whole-grown” protein it says requires no extra processing or genetic modification, yielding a more robust nutritional profile than many plant-based seafood options. Its inherently flavorless base can be fine-tuned late in the growth process to create textures and flavors for products such as tuna, whitefish, calamari, shrimp, and scallops. Founded in 2020 and based in Chicago, Aqua Cultured Foods raised $2.1 million in pre-seed funding to support rapid growth. The startup is targeting 2022 for commercial releases, initially via limited-time foodservice offerings with retail planned later, and reports early sales interest and strategic partnerships. The new capital will be used to build the team and accelerate R&D to iterate on texture, shape, nutritional value, and flavor to bring products closer to animal-derived versions.